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A B S T R A C T
Bone fractures are common comorbidities of type 2 diabetes mellitus (T2DM). Bone fracture incidence seems to
develop due to increased risk of falls, poor bone quality and/or anti-diabetic medications. Previously, a relation
between gut hormones and bone has been suspected. Most recent evidences suggest indeed that two gut hor-
mones, namely glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), may
control bone remodeling and quality. The GIP receptor is expressed in bone cells and knockout of either GIP or
its receptor induces severe bone quality alterations. Similar alterations are also encountered in GLP-1 receptor
knock-out animals associated with abnormal osteoclast resorption. Some GLP-1 receptor agonist (GLP-1RA) have
been approved for the treatment of type 2 diabetes mellitus and although clinical trials may not have been de-
signed to investigate bone fracture, first results suggest that GLP-1RA may not exacerbate abnormal bone quality
observed in T2DM. The recent design of double and triple gut hormone agonists may also represent a suitable
alternative for restoring compromised bone quality observed in T2DM. However, although most of these new
molecules demonstrated weight loss action, little is known on their bone safety. The present review summarizes
the most recent findings on peptide-based incretin therapy and bone physiology.
1. Introduction
Diabetes mellitus is progressing worldwide. A report from the In-
ternational Diabetes Federation estimated that 415 million individuals
were suffering of diabetes mellitus worldwide in 2015. Projections for
2040 estimate a burden at approximately 642 million individuals [1].
Diabetes mellitus is characterized by a decrease in production of insulin
(type 1 diabetes mellitus – T1DM) or by resistance to insulin (type 2 di-
abetes mellitus – T2DM) that ultimately result in higher circulating glu-
cose concentrations.
Among all complications associated with diabetes mellitus, bone
fractures represent a significant health issue for patients with T1DM or
T2DM. Etiology of bone fracture in diabetes mellitus has recently been
the topic of several reviews and as such will not be discussed further
in the present paper [2–4]. However, it seems that in diabetes, frac-
tures occur as a consequence of increased risk of falls, low bone quality
and bone turnover, and may be exacerbated by anti-diabetic medica-
tions such as thiazolidinediones or SGLT2 inhibitors [5]. Management of
fracture prevention relies on improving glycemic control and reducing
falls. However, it is important to bear in mind that no diabetes-spe-
cific guidelines for fracture prevention exist although it is admitted that
those appropriate for older adults in general delineate strategies that are
also applicable to those with diabetes. However, these guidelines have
been established for patients with low bone mineral density and may
not reflect what happens in T2DM, where bone mineral density may
be normal or slightly higher. Concerns regarding the use of anti-resorp-
tive strategies (bisphosphonate, raloxifene, denosumab), that may fur-
ther reduce the already existing low bone turnover, have also been ex-
pressed [6] and may not be the most suitable intervention especially
with regards to the higher occurrence of atypical femoral fracture in
postmenopausal women with diabetes [7]. Anabolic agents such as teri-
paratide may represent a more suitable approach in diabetes, but al-
though positive data have been reported in pre-clinical animal studies,
human data are scarce [8].
The gastrointestinal (GI) tract is one of the largest endocrine organs
with more than 12 specialized endocrine cells [9]. Among the plethora
of bioactive peptides that the GI tract secretes, a class of peptides
called incretins has emerged as important modulators of energy metab-
olism. The term “incretin” was initially proposed by Creutzfeld in 1979
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and represents hormones that are secreted from the intestine in response
to glucose and stimulate insulin release in a glucose-dependent man-
ner [10]. Although several hormones with insulinotropic action are se-
creted by the gut, glucose-dependent insulinotropic polypeptide (GIP)
and glucagon-like peptide-1 (GLP-1) are the only two physiological in-
cretins identified so far [11]. Based on the glucose-lowering properties
of GLP-1, several GLP-1 receptor agonists have been designed and ap-
proved for the treatment of T2DM. Recently, based on knockout preclin-
ical animal models, potential beneficial effects of both GIP and GLP-1
have been highlighted and may represent a suitable therapeutical op-
tion in the treatment of diabetes-induced bone fragility. The goal of the
present review is to summarize the beneficial bone effects of GIP, GLP-1
and GLP-1 receptor agonist.
2. Glucose-dependent insulinotropic polypeptide (GIP)
GIP is produced and secreted mostly by intestinal K-cells, located pri-
marily in proximal regions of the small intestine. The K-cell is highly po-
larized with the GIP-containing secretory granules concentrated at the
basal pole of the cell and released through the basolateral membrane
upon stimulus [12,13]. Based on the morphological features, GIP secre-
tion from K-cells is regulated by neural stimuli, hormones and intralu-
minal contents [14]. K-cells are found in close association with the cap-
illary network running through the lamina propria allowing GIP to enter
into the blood stream rapidly after secretion. Furthermore, intraluminal
contents do not only affect GIP secretion but also GIP expression. In-
deed, glucose and lipids are potent stimulators of GIP gene transcription
[15,16].
Recent evidences suggested that the GIP/GIP receptor (GIPr) path-
way is an important regulator of bone physiology. The first argument
is represented by the expression at the mRNA and protein levels of the
GIPr in osteoblasts and osteoclasts [17–20]. Interestingly, the expression
of the GIPr is augmented in murine osteoblast by glucose treatment in
the presence of BMP-2 [21]. In osteoblast cultures, GIP administration
results in increases in intracellular calcium and cAMP that lead to aug-
mentations in type I collagen expression, alkaline phosphatase and lysyl
oxidase activities, and higher enzymatic collagen cross-linking [18,22].
In osteoclast cultures, GIP is capable of reducing the extent of osteoclast
formation and resorption by fully mature human and murine osteoclasts
through direct inhibitions of calcium oscillation and NFATc1 nuclear
translocation after RANKL stimulation [20,23,24].
The phenotype of GIP- and GIPr-deficient animals has been pre-
viously reported. GIP-GFP-KI mice, generated by the insertion of an
EGFP-poly(A)-loxp-Neo-loxp cassette into exon 3 of wild type Gip gene,
are defective in releasing GIP [25]. These mice present with a lower tra-
becular bone mass associated with higher osteoclast surface [26]. Inter-
estingly, conflicting results have been reported in mice lacking a func-
tional GIPr. Indeed, two animal models have been generated: the first
one lacks exons 4 and 5 of the mouse Gipr gene and seems to exhibit
lower trabecular bone mass [24,27]. The second model lacks exons 1–6
and exhibits a high trabecular bone mass and a low cortical bone mass
associated with alterations of bone quality [28,29]. However, as the lack
of a functional GIPr leads to increased GLP-1 sensitivity [30–32], we
wondered whether the observed bone phenotype observed in GIPr KO
mice resulted from the direct lack of GIPr or by a compensatory mecha-
nism induced by elevated sensitivity to GLP-1. To answer this question,
the bone phenotype of double incretin receptor knockout (DIRKO) ani-
mals, lacking both the GIPr and GLP-1r, was investigated [33]. DIRKO
animals also exhibit profound reductions in bone mass, as well as, alter-
ations of trabecular and cortical microarchitectures and tissue material
properties demonstrating the important role of incretins in bone physi-
ology.
Physiologically, circulating levels of intact bioactive GIP are ex-
tremely low due to rapid degradation in the mucosa of the small intes-
tine by hematopoietic- and endothelial cell DPP4 directly after its se-
cretion [34]. As such, several GIP analogues have been developed to be
enzymatically resistant to degradation [35]. Preclinical data on the use
of GIP mimetic in animal models are scarce nevertheless, administra-
tion of N-Acetyl-GIP (N-AcGIP) ameliorated tissue material properties
when administered for 28 days in healthy rodents [36]. Furthermore, in
streptozotocin-injected mice, developing a classical picture of type 1 di-
abetes, with a compromised bone mass and microarchitecture as well as
tissue material properties, the administration of [D-Ala⁠2]GIP for 21 days
resulted in bone turnover almost similar to non-diabetic animals, and
reduction in matrix collagen destruction [37]. These results are very in-
teresting as insulin release was unchanged in [D-Ala⁠2]-treated as com-
pared with saline-treated mice, suggesting that these beneficial effects
of GIP mimetic are independent of insulin secretion.
In healthy humans, although initially GIP had been shown ineffec-
tive in reducing bone resorption [38], recent evidences suggested that
exogenous administration of GIP was effective in reducing circulating
markers of bone resorption [39]. However, whether these results reflect
direct actions of GIP on osteoclast-mediated resorption or indirect ac-
tions of other GIP-targeted tissues remain to be determined in the fu-
ture. Furthermore, the link between GIP/GIPr pathway and bone mass/
strength is definitely established and represented by low mineral bone
density at the femoral neck and total hip, as well as higher incidence
of non-vertebral fractures, in a cohort of perimenopausal women with a
single-nucleotide polymorphism (rs1800437), that results in decreased
GIPr activity [40,41].
3. Glucagon-like peptide-1 (GLP-1)
GLP-1 is produced and secreted by enteroendocrine L-cells after pro-
cessing of the proglucagon gene [11]. Despite two forms of GLP-1 might
be produced in the intestine, GLP-1⁠7-36NH2 is the major form [42]. As
K-cells, L-cells are also open type endocrine cells highly polarized with
secretory granules at their basolateral pole. GLP-1 secretion from L-cells
is regulated by intraluminal contents, neural stimuli and hormones [43].
L-cells are found in close association with the capillary network running
through the lamina propria. GLP-1 has also been suspected to act via the
autonomous nerve system and vagal afference on specific hypothalamic
and brainstem nuclei to exert its action [44]. GLP-1 is rapidly degraded
in the mucosa of the small intestine by endothelial cell DPP4.
Presence of the known GLP-1r in bone cells was controversial un-
til recently. Indeed, this confusion was due to the use of poorly char-
acterized cell lines [17], selection of wrong primer pairs [45], or the
use of non-selective anti-GLP-1r antibodies [21] that were not very spe-
cific of the mouse Glp1r gene. Recent evidences by Pereira et al. seem
to suggest the presence of the known GLP-1r in skeletal tissues [46].
However, other studies failed to demonstrate the presence of GLP-1r
in MC3T3-E1 [47] or primary murine osteoblasts or osteoclasts [28]
and this discrepancy needs to be investigated in the future. Neverthe-
less, previous studies in other tissues such as liver and skeletal mus-
cle revealed the presence of a second GLP-1 receptor different from the
known GLP-1r in function and/or structure. Indeed, this second GLP-1
receptor does not activate the cAMP pathway as GLP-1r does but rather
the production of inositolphosphoglycan as a second messenger [48,49].
Nuche-Berenguer et al. revealed the presence of this second GLP-1 re-
ceptor in the MC3T3-E1 murine osteoblastic cell line [47]. However, as
recent evidences pointed out that GLP-1 could bind to the glucagon re-
ceptor in certain circumstances [50], it would be compulsory to ascer-
tain whether this second GLP-1r corresponds to a modulation of ligand
specificity at the glucagon receptor.
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The bone phenotype of GLP-1r KO revealed an interesting bone phe-
notype. These animals exhibit reductions in trabecular bone volume and
cortical thickness, altered bone strength and compromised bone qual-
ity [51,52]. At the cellular level, the number of osteoclasts and eroded
surfaces were increased with no apparent effects on osteoblast activity
[52]. Taken together these results suggested a control of bone resorp-
tion (osteoclast differentiation and/or action) by the GLP-1r despite no
direct action of GLP-1 in controlling osteoclast formation and resorp-
tion in osteoclast cultures [52]. However, in humans, administration of
exogenous GLP-1 does not result into lower CTx levels [38]. Recently,
evidences have been provided that the GIPr was expressed by C-cells of
the thyroid gland in rodents, but not in non-human primate or humans,
and responsible for calcitonin secretion [53]. Taken together, these ob-
servations highlight that a functional GLP-1r is not only required for the
control of bone resorption but also for the preservation of an optimal
bone matrix quality.
Several GLP-1 receptor agonists resistant to DPP4 degradation have
been designed and recently approved for the treatment of T2DM [54].
Among them, exenatide (also known as exendin-4) and liraglutide rep-
resent the leading molecules. GLP-1r is expressed by mesenchymal
stem cells present in the bone marrow. Activation of GLP-1r by GLP-1
maintains proliferation of MSC and blocks their differentiation into
adipocytes by modulating key adipocyte gene [55]. Furthermore, exe-
natide has been shown to protect MSC from apoptosis and endoplas-
mic reticulum stress [56]. GLP-1 and its analogues also modulate os-
teoblast proliferation and differentiation by activating different intracel-
lular pathways, namely PI3K/Akt, ERK 1/2, cAMP/PKA, AMPK/mTOR
and c-fos [57–61]. On the other hand, few data are available on the ef-
fect of GLP-1 or its analogue in the differentiation and activation of os-
teoclast cells in vitro. Several pre-clinical and proof-of-concept studies
have been undertaken in animal models with skeletal fragility (T1DM,
T2DM and OVX-induced osteoporosis). Mechanistically, administration
of GLP-1⁠7-36NH2 or exenatide, a GLP-1r agonist, results in a rapid aug-
mentation of osteocalcin gene expression and, reductions in sclerostin
expression and in the balance RANKL/OPG [45,62,63]. In type-1 dia-
betes mellitus, administration of liraglutide for 21 days contributed to
significant improvement in bone strength at the tissue levels and re-
duction in collagen degradation in the bone matrix [37]. However, no
improvements in neither trabecular nor cortical bone microarchitecture
were observed. Nevertheless, these mild ameliorations occurred in the
absence of insulin secretion. Due to the marketing of GLP-1 mimetic for
type 2 diabetes, the efficacy of GLP-1 analogues has been performed in
type 2 diabetic rodent models. In this condition, the administration of
liraglutide ameliorated trabecular and cortical bone microarchitectures
[64]. It is, however, worth noting that the administration of liraglutide
has been performed at a dose regiment of 0.4 mg/kg/day as compared
with the 0.02 mg/kg/day used in human clinical trials [65,66]. The ef-
fects of GLP-1 mimetic have also been conducted in osteoporotic rodent
models. Indeed, 16 weeks administration of exenatide (dose regimen of
10 μg/kg/day similar to the dose used in humans [67]) in OVX rats,
is capable of improving trabecular bone mass and microarchitecture at
the femur and lumbar vertebra, bone strength and revert hyper-resorp-
tion observed after ovariectomy [68]. Furthermore, these results were
confirmed by Pereira et al. [46]. It is also noteworthy that at this dose
regimen, exenatide was incapable of reversing the observed deterio-
ration of cortical microarchitecture. Pereira et al., also reported posi-
tive effects of liraglutide (0.3 mg/kg/day) in improving trabecular but
not cortical microarchitecture [46]. However, administration of liraglu-
tide at a dose of 1.8 mg/kg/day for 8 weeks, significantly improved
trabecular and cortical microarchitecture [69]. This dose regimen is
90 times more elevated than the dose given to humans. Moreover, re-
cently, evidences have been provided that undercarboxylated osteocal-
cin was capable of inducing GLP-1 release from the L-cells and as such,
this complementary mechanism reinforced the role of osteocalcin in en-
ergy expenditure [70,71].
Although now several GLP-1 receptor agonists have been approved
for the treatment of T2DM, data regarding the safety and efficacy of
such approach on bone strength and fracture risk is scarce. In 2014, we
conducted the first meta-analysis of randomized clinical trials of GLP-1
receptor agonist based on the little amount of data available at that
time [72]. Our study included 2918 patients treated with a GLP-1RA
and 1337 treated with a comparator. This meta-analysis reported that
the risk of developing a bone fracture was not elevated (OR 0.75 [95%
CI 0.28–2.02], but also not reduced as one could have expected from
pre-clinical data, in T2DM patients. A year later, Su et al., reassessed this
risk by performing a meta-analysis including 5040 patients treated with
a GLP1RA and 3410 treated with a comparator [73]. The overall assess-
ment confirmed the above findings (OR 1.05 [95% CI 0.59–1.87]. How-
ever, as the number of patients was greater, a molecule-based analysis
was conducted and highlighted a possible reduction of the risk of frac-
ture with liraglutide (OR 0.38 [95% CI 0.17–0.87] and a higher risk
with exenatide (OR 2.09 [95% CI 1.03–4.21]. Retrospective case-control
studies based on the Clinical Practice Research Datalink and the Danish
National Health Service registry demonstrated a neutral role of GLP-1RA
on fracture risk [74,75]. Recently, Paschou et al. summarize the most
recent evidences on the skeletal effects of GLP-1RA on fracture risk and
reached the conclusion that although a controlled trials designed to as-
sess the fracture risk under GLP-1RA treatment with bone fracture as
the primary outcome is still lacking, GLP-1RA therapy seems neutral in
term of bone metabolism and fracture risk [76].
4. Double and triple analogue molecules
Recently, double and triple agonists of gut hormone receptors have
been designed and successfully synthesized (Table 1). The rationale be-
hind using these double and triple molecules arises from the additive
effects brought by co-administration of single receptor agonists. The
majority of double and triple agonists exhibit action at the GLP-1r,
glucagon receptor (GCGr), GIPr and cholecystokinin B receptor (CCK
BR). All these molecules showed positive effects on plasma glucose and
weight loss in rodent models of T2DM [77–86] but little information has
been provided in term of bone strength apart from [D-Ala⁠2] GIP-Oxm.
This data would be very interesting in order to ascertain the safety of
such therapeutical intervention as weight loss is often consider as a neg-
ative factor for bone strength, especially in overweight and obese pa-
tients [87,88]. NNC0090-2746 has also recently been successfully used
in a 12 week, randomized, placebo-controlled, double blind phase 2a
trial of patients with T2DM inadequately controlled with metformin
[89]. Apparently, no fracture occurs in both arms (NNC0090-2746- and
placebo-treated) but the relatively low amount of patients included in
this phase 2a trial (37 patients treated with 1.8 mg NNC0090-2746
and 36 patients treated with placebo) might not have been enough
to highlight bone safety of this therapeutical approach. Currently, the
only available data are those provided by Mansur et al., who inves-
tigated bone strength in the db/db mouse model after administration
of [D-Ala⁠2] GIP-Oxm. It seems that [D-Ala⁠2] GIP-Oxm significantly im-
proved bone strength at the organ and tissue level [90]. This improved
bone strength was mediated through ameliorations of trabecular bone
microarchitecture and collagen maturity and lower collagen glycation.
5. Conclusions
A clear link between incretins and bone physiology has been demon-
strated and incretins appear as potent modulators of bone mass but
also of bone quality and ultimately bone strength. However, the ma-
jor challenge to face in this field in the future will be to ascertain by
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Table 1
Summary of double and triple agonists exploiting the incretin pathway.
Name Peptide sequence Agonism at Reference
Aib2 C24 lactam 40k HXQGTFTSDYSKYLDEQAAKEFIC ⁠aWLMNT⁠-NH2 GLP1r, GCGr [78]
DualAG HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-Cholesterol GLP1r, GCGr [85]
ZP 2495 HSQGTFTSDYSKYLDRARADDFVAWLKST ⁠-NH2 GLP1r, GCGr [90]
[D-Ala⁠2]GLP1/GcG Y[D-Ala]EGTFISDYSKYLDSRRAQDFIAWLVKGR ⁠-NH2 GLP1r, GCGr [82]
ZP 3022 HGEGTFTSDLSKQMEEEAVRLFIEWLKN-8Ado-8Ado-YGWLDF ⁠-NH2 GLP1r, CCK-BR [81]
Twinincretin (Compound 18) YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSK ⁠-NH2 GIPr, GLP1r [79]
NNC0090-2746 (RG7697 or compound 19) YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSK⁠-NH2 GIPr, GLP1r [79]
Compound 21 YXEGTFTSDYSIYLDKQAAXEFVC*WLLAGGPSSGAPPPSK ⁠-NH2 GIPr, GLP1r [79]
[D-Ala⁠2]GIP-Oxm Y[D-Ala]EGTFISDYSKYLDSRRAQDFVQWLMNTKRNRNNIA GIPr, GLP1r, GCGr [76]
YAG-Glucagon Y[D-Ala]QGTFTSDYSIYLDSNVAQDFVQWLIGG GIPr, GLP1r, GCGr [77]
Triagonist HXQGTFTSDKSKYLDERAAQDFVQWLLDGGPSSGAPPPS ⁠-NH2 GIPr, GLP1r, GCGr [80]
(pGlu-Gln)-CCK-8/Exendin-4 H(pE)QDYMGWMDFZZHGEGTFTSDLSKQMEEEAVRLFIEWLKN ⁠-NH2 GLP1r/CCK-BR [84]
GIP/Xenin Y[D-Ala]EGTFISDYSIAMHPQQPWIL GIPr, NT1R? [83]
X is aminoisobutyric acid, Z is {2-[2-aminoethoxy]ethoxy}acetic acid. Side chains of underlined amino acids are covalently coupled. Italic letters represent site of acylation.
a PEGylation.
which mechanisms incretins exert their control on skeletal physiology
and to demonstrate the efficacy of incretin therapies in bone diseases
with compromised bone strength. Furthermore, as the use of double and
triple agonists seems promising, it will also be a prerequisite to ascer-
tain their effects on bone strength more in detail.
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